ERBB2 and breast carcinoma: On these grounds, the nearly physiological number of circulating Tregs displayed by stage II and III HER2+ breast cancer patients may imply a favorable background for NK-involving therapy such as monoclonal antibodies (trastuzumab), and may further benefit from the spontaneous enhanced antitumor T cell responses.